JP2021529559A5 - - Google Patents
Info
- Publication number
- JP2021529559A5 JP2021529559A5 JP2021522932A JP2021522932A JP2021529559A5 JP 2021529559 A5 JP2021529559 A5 JP 2021529559A5 JP 2021522932 A JP2021522932 A JP 2021522932A JP 2021522932 A JP2021522932 A JP 2021522932A JP 2021529559 A5 JP2021529559 A5 JP 2021529559A5
- Authority
- JP
- Japan
- Prior art keywords
- immune cell
- nucleotide sequence
- immune
- cancer
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076738A JP2024102286A (ja) | 2018-07-03 | 2024-05-09 | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693677P | 2018-07-03 | 2018-07-03 | |
| US201862693668P | 2018-07-03 | 2018-07-03 | |
| US62/693,668 | 2018-07-03 | ||
| US62/693,677 | 2018-07-03 | ||
| US201862713369P | 2018-08-01 | 2018-08-01 | |
| US62/713,369 | 2018-08-01 | ||
| US201862756698P | 2018-11-07 | 2018-11-07 | |
| US201862756664P | 2018-11-07 | 2018-11-07 | |
| US62/756,698 | 2018-11-07 | ||
| US62/756,664 | 2018-11-07 | ||
| PCT/US2019/040346 WO2020010110A1 (en) | 2018-07-03 | 2019-07-02 | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076738A Division JP2024102286A (ja) | 2018-07-03 | 2024-05-09 | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529559A JP2021529559A (ja) | 2021-11-04 |
| JP2021529559A5 true JP2021529559A5 (enExample) | 2022-07-12 |
Family
ID=69060204
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522932A Pending JP2021529559A (ja) | 2018-07-03 | 2019-07-02 | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
| JP2024076738A Pending JP2024102286A (ja) | 2018-07-03 | 2024-05-09 | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076738A Pending JP2024102286A (ja) | 2018-07-03 | 2024-05-09 | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3817763B1 (enExample) |
| JP (2) | JP2021529559A (enExample) |
| KR (1) | KR20210030950A (enExample) |
| CN (1) | CN112638402A (enExample) |
| AU (1) | AU2019299439C1 (enExample) |
| CA (1) | CA3104862A1 (enExample) |
| IL (1) | IL279629A (enExample) |
| WO (1) | WO2020010110A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7241161B2 (ja) | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| JP7456638B2 (ja) | 2018-08-14 | 2024-03-27 | ソティオ，リミティド ライアビリティ カンパニー | クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| CN115315510A (zh) * | 2020-01-28 | 2022-11-08 | 免疫生物公司 | 靶向egfr超家族受体的嵌合抗原受体修饰的nk-92细胞 |
| CA3185234A1 (en) * | 2020-07-09 | 2022-01-13 | Dorota Danuta KLYSZ | Immune cells with increased glycolytic flux |
| WO2022140361A1 (en) * | 2020-12-22 | 2022-06-30 | Ludwig Institute For Cancer Research Ltd | Genetically engineered lymphocytes for adoptive cell therapy |
| WO2022177970A1 (en) * | 2021-02-18 | 2022-08-25 | University Of Florida Research Foundation, Incorporated | Enhancing metabolic fitness of t cells to treat cancer |
| EP4326292A4 (en) * | 2021-04-23 | 2025-03-26 | Vivasor, Inc. | Dimeric antigen receptors (dars) that bind gd2 |
| WO2023049933A1 (en) | 2021-09-27 | 2023-03-30 | Sotio Biotech Inc. | Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof |
| WO2023081455A2 (en) * | 2021-11-08 | 2023-05-11 | Memorial Sloan-Kettering Cancer Center | Immune cells expressing glucose transporter 5 (gluts) and compositions and methods including the same |
| AU2022388928A1 (en) | 2021-11-16 | 2024-05-16 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| GB202118201D0 (en) | 2021-12-15 | 2022-01-26 | King S College London | Engineered immune cell |
| KR20240154656A (ko) * | 2022-03-08 | 2024-10-25 | 신테카인, 인크. | 직교 gpc3 키메라 항원 수용체 t 세포 |
| CN115678856A (zh) * | 2022-06-09 | 2023-02-03 | 郑州大学第一附属医院 | 一种肿瘤杀伤细胞及其应用 |
| WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
| WO2024040208A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| WO2025150523A1 (ja) * | 2024-01-09 | 2025-07-17 | 国立研究開発法人国立がん研究センター | オンデマンドにグルコース取り込み能が強化されたｔ細胞、細胞集団およびそれを含む医薬組成物 |
| JP7685726B1 (ja) * | 2024-01-09 | 2025-05-30 | 国立研究開発法人国立がん研究センター | サバイバーｔ細胞、サバイバーｔ細胞集団および医薬組成物 |
| TW202540409A (zh) * | 2024-01-09 | 2025-10-16 | 國立研究開發法人國立癌症研究中心 | 存活ｔ細胞、存活ｔ細胞集團及醫藥組成物 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU7477394A (en) | 1993-07-30 | 1995-03-27 | University Of Medicine And Dentistry Of New Jersey | Efficient gene transfer into primary lymphocytes |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| US5756910A (en) | 1996-08-28 | 1998-05-26 | Burgett, Inc. | Method and apparatus for actuating solenoids in a player piano |
| WO1998022588A2 (en) | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU2474700A (en) | 1998-12-01 | 2000-06-19 | Genentech Inc. | Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
| WO2000063374A1 (en) | 1999-04-16 | 2000-10-26 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| AU2271801A (en) * | 1999-12-21 | 2001-07-03 | Zymogenetics Inc. | Human slit polypeptide zslit3 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| KR102308597B1 (ko) | 2013-10-17 | 2021-10-01 | 내셔널 유니버시티 오브 싱가포르 | 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체 |
| EP3074419B1 (en) * | 2013-11-25 | 2018-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
| CA2972714A1 (en) | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
| US11020429B2 (en) * | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| EP3430036A4 (en) | 2016-03-18 | 2019-08-14 | Unum Therapeutics | MODIFIED CHIMERIC RECEPTORS AND USES IN IMMUNOTHERAPY |
| EP4628587A3 (en) * | 2016-04-15 | 2026-02-25 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| CN105949324B (zh) * | 2016-06-30 | 2019-08-27 | 上海恒润达生生物科技有限公司 | 靶向gpc3的嵌合抗原受体及其用途 |
| CN112481217A (zh) * | 2016-09-01 | 2021-03-12 | 嵌合体生物工程公司 | Gold优化的car t-细胞 |
| ES2981703T3 (es) * | 2016-09-02 | 2024-10-10 | Lentigen Tech Inc | Composiciones y métodos para tratar cáncer con DuoCars |
| BR112019006781A2 (pt) * | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| KR20210056377A (ko) * | 2018-09-07 | 2021-05-18 | 소티오, 엘엘씨 | 세포내 락테이트 농도를 조절하는 트랜스 대사 분자와 조합된 키메라 수용체 폴리펩타이드 및 이의 치료 용도 |
-
2019
- 2019-07-02 AU AU2019299439A patent/AU2019299439C1/en active Active
- 2019-07-02 CN CN201980056724.9A patent/CN112638402A/zh active Pending
- 2019-07-02 CA CA3104862A patent/CA3104862A1/en active Pending
- 2019-07-02 EP EP19831325.6A patent/EP3817763B1/en active Active
- 2019-07-02 KR KR1020217003418A patent/KR20210030950A/ko not_active Ceased
- 2019-07-02 JP JP2021522932A patent/JP2021529559A/ja active Pending
- 2019-07-02 WO PCT/US2019/040346 patent/WO2020010110A1/en not_active Ceased
-
2020
- 2020-12-21 IL IL279629A patent/IL279629A/en unknown
-
2024
- 2024-05-09 JP JP2024076738A patent/JP2024102286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529559A5 (enExample) | ||
| JP2021536265A5 (enExample) | ||
| JP2021534740A5 (enExample) | ||
| US12410248B2 (en) | Chimeric antigen receptor and its use | |
| JP7490915B2 (ja) | 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用 | |
| JP7175769B2 (ja) | 改善された養子ｔ細胞療法 | |
| US12076378B2 (en) | Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors | |
| Guest et al. | The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens | |
| EP2709671B1 (en) | Method | |
| JP2022512958A5 (enExample) | ||
| CN109053899B (zh) | 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体 | |
| JP2024023228A5 (enExample) | ||
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| CN109280086B (zh) | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 | |
| JP2024536859A5 (enExample) | ||
| US20220298223A1 (en) | B CELL TARGETED PARALLEL CAR (pCAR) THERAPEUTIC AGENTS | |
| WO2018045034A1 (en) | Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain | |
| EP3098237A1 (en) | Anti-toso chimeric antigen receptor and its use | |
| WO2019115818A2 (en) | Pooling signaling and costimulatory domains in flexible car design | |
| Vyas et al. | Mono-and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia | |
| JP2022551455A (ja) | 操作された免疫細胞 | |
| EP4210733B1 (en) | System for inducible expression of an adapter in immune cells | |
| CN119301157A (zh) | 用于癌症治疗的抗活化的Trop-2的嵌合抗原受体构建体 | |
| Shibaguchi et al. | Cloning and sequencing of variable region cDNAs of a novel human monoclonal antibody to carcinoembryonic antigen, and generation of a single chain variable fragmented antibody | |
| NZ772146B2 (en) | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |